Boris Pasche and Alexandre Barbault, coinventors of the TheraBionic technology and cofounders of TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH, had one goal in mind since the beginning of their research: developing better and safer therapies for cancer.

Since 2001 they have developed a proprietary technology as well as proprietary devices to identify tumor-specific modulation frequencies. Identification of these frequencies was based on changes in hemodynamic parameters occurring when patients are exposed to low and safe radiofrequency electromagnetic fields, which are amplitude-modulated from 0.1 Hz to 150 kHz. Using this approach, they discovered that patients with the same tumor type, e.g. hepatocellular carcinoma, had the same hemodynamic changes when exposed to the same frequency modulations.

Following identification of tumor-specific frequencies they hypothesized that these frequencies could block cancer growth. They designed and built new devices emitting the same modulation frequencies as those identified in patients. Treatment was administered for 60 minutes 3 times a day. In two separate clinical studies they found that this treatment was capable of blocking tumor growth in a substantial proportion of patients without causing any side effects of significance.

The vision of TheraBionic’s founders is to further expand their findings using this technology both for diagnosis and treatment of several forms of cancer.

TheraBionic GmbH services

Therapy of Hepatocellular Carcinoma